The 1^st generation of cell therapies uses DNA-based vectors including plasmids and lentivirus, and has demonstrated its efficiency. However, it also raises some questions regarding biosafety, cost, and compatibility with high throughput production. Now, the messenger RNA approach can avoid the genome integration, is safer and can ensure low immune response. So, why not use mRNA for cell therapies?

Many researchers are facing the challenges of mRNA delivery, through the body into the cytoplasm of cells. In this post, we invite you to discover some useful and efficient solutions to improve and control all the steps of your mRNA delivery project.

Propelled into the spotlight by the COVID-19 pandemic, mRNA has become a biological entity of great interest in drug discovery – yet mRNA vaccines are just the promising beginning, leading to more and more discoveries and applications. mRNA demonstrates high potential to cure numerous other diseases, as we invite you to discover in this post – let’s take a look at a number of other mRNA based applications with active R&D, establishing mRNA beyond a current trend.

Synthetic mRNA is indeed the highway for today’s therapeutics, whether you’re working on developing new drugs against cancer targets, or whether you aim to develop new vaccines, Covid-19 being one of them. So, how can you obtain your mRNA within just a few weeks, ready to explore these potential applications? Read on to see how we can help you achieve this.